대웅제약, '펙수클루' 위궤양 적응증 확대 임상 3상 신청

Daewoong Pharmaceutical is strategically expanding Fexuclue's therapeutic range to include Gastric Ulcer through multi-national Phase 3 trials. This expansion is crucial for strengthening its competitive edge in the gastrointestinal drug market and maximizing the commercial value of its flagship P-CAB class medication.